agents of interest being explored in essential thrombocythemia and polycythemia vera
Published 1 year ago • 241 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
1:25
exciting updates in essential thrombocythemia: exploring novel agents
-
1:39
upcoming agents in et and pv
-
3:29
unmet needs and therapeutic strategies in essential thrombocythemia
-
0:35
novel therapeutics in essential thrombocythemia
-
4:48
an insight into the management of cytopenias in mf
-
2:24
update on phase iib study of bomedemstat in essential thrombocythemia
-
3:21
the current standard of care for patients with essential thrombocythemia
-
2:06
clinical updates on the use of ropeginterferon for polycythemia vera
-
26:22
key takeaways in mpns
-
6:09
signs of progressive polycythemia vera
-
1:09:45
living with polycythemia vera
-
4:10
the management of polycythemia vera with cytoreductive drug therapy
-
3:23
the role of rusfertide in polycythemia vera
-
0:59
developing lsc-targeting agents in aml: progress and current therapeutic capacity
-
5:42
an update on revive: rusfertide in patients with polycythemia vera
-
3:54
an insight into how novel agents are influencing survival outcomes in patients with mf
-
4:22
molecular profile impacts platelet function and thrombin generation in essential thrombocythemia
-
5:21
challenges in the treatment and management of et and the need to improve therapeutic approaches
-
2:05
the surpass-et study: evaluating novel treatment approaches in et
-
1:32
shifting the treatment landscape of itp: novel agents and future outlooks
-
2:46
an update on emerging therapies for the treatment of polycythemia vera
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf